Responses to parliamentary questions
Question from Deputy Ken O’Flynn - PQ 39831-26
Deputy O'Flynn asked about the Irish reimbursement assessment process for omaveloxolone (Skyclarys®). Read the HSE response.
From: Communications and public affairs
Published: May 2026
Updated: July 2026
Documents
Question from Deputy Ken O’Flynn - PQ 39831-26
PDF, 469KB, 3 pages
Summary
To ask the Minister for Health whether the HSE formally reviewed reimbursement, managed access, or pricing decisions relating to omaveloxolone (skyclarys) in France, Germany, Italy, Spain, Belgium, the Netherlands or the United Kingdom as part of the Irish reimbursement assessment process; and if she will provide details of any such comparative analysis undertaken.
This is a beta version - your feedback will help us to improve it